The United States Food and Drug Administration (US FDA) has made an urgent appeal to the Indian Drug Manufacturers’ Association (IDMA) for assistance in identifying pharmaceutical companies capable of supplying ifosfamide injections. This critical chemotherapy drug, used in treating testicular, bladder, and lung cancers, is currently facing a severe shortage across the US.
Understanding the Supply Crisis
The shortage of ifosfamide has been attributed to a confluence of factors. Baxter International, a primary supplier of the drug in the US, encountered technical issues at one of its contract manufacturing facilities. Simultaneously, ongoing geopolitical tensions in West Asia have caused significant disruptions to global supply chains, affecting the movement of both active pharmaceutical ingredients and finished medicines.
According to reports, the FDA's drug shortage database listed several strengths of ifosfamide as unavailable or in limited supply as of mid-June. The regulator indicated that while production has resumed, it remains below the required levels to meet demand, with the shortage potentially extending through 2026.
India's Role in Bridging the Gap
In an unusual move, the US FDA has indicated a willingness to consider supplies from Indian facilities that may not be currently registered with the US regulator, as well as products approved and sold in markets outside the United States. While preference will be given to FDA-registered facilities, the agency is open to information from those with a demonstrated history of satisfactory regulatory compliance.
India possesses a robust pharmaceutical industry, with several companies like Cipla, Zydus Lifesciences, Alkem Laboratories, and GLS Pharma already manufacturing ifosfamide. India's oncology drugs and cancer treatment market is substantial, and the country has a significant track record of exporting anti-cancer medicines to the US.
Industry Response and Outlook
The IDMA has communicated the FDA's request to its members, asking manufacturers to provide details such as production facility location, FDA establishment identifier numbers, available product strengths, and regulatory status in other markets. Viranchi Shah, IDMA’s national spokesperson, confirmed that the association is actively gathering information from firms capable of supplying the necessary products.
This outreach highlights the interconnectedness of global pharmaceutical supply chains and India's growing importance as a reliable source of essential medicines, particularly during times of international crisis.